ArticleCancers2022

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.

Camille Domergue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.